Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Benzinga · 1d ago
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.